A single injection into the cochlea. That’s all it takes for Otarmeni to potentially restore hearing in patients born deaf due to OTOF gene mutations. On April 23, 2026, the FDA approved this dual AAV vector-based therapy from Regeneron Pharmaceuticals, marking the first gene treatment for genetic hearing loss. Patients with severe-to-profound sensorineural hearing loss—greater than 90 dB HL at any frequency—now have a one-time option. No batteries. No implants. Just biology fixed at the source.
The OTOF gene codes for otoferlin, a protein essential for inner hair cells to transmit sound signals to the auditory nerve. Biallelic variants disrupt this process entirely. Sound waves vibrate the hair cells, but the signal dies there. Before Otarmeni, cochlear implants offered the only recourse, electrically bypassing the faulty biology. Effective, yes. But artificial.
Regeneron acquired the program—originally DB-OTO—from Decibel Therapeutics in 2023. The therapy delivers a functional OTOF copy via two AAV1 vectors, split to handle the gene’s size. Surgeons infuse it directly into the cochlea using a syringe, catheter, and pump under general anesthesia. One ear per treatment. Preserved outer hair cell function required; no prior implants in that ear.
Trial data drove the approval. The phase 1/2 CHORD study enrolled 24 pediatric patients, ages 10 months to 16 years. Of 20 evaluable for efficacy, 80% showed hearing improvements by week 24, measured via pure tone audiometry. Natural history expects no such gains. Some reached normal thresholds below 25 dB HL. Three patients hit whisper-hearing levels. Sustained otoferlin expression confirmed the mechanism.
“Today’s approval is a significant milestone in the treatment of genetic hearing loss,” said FDA Commissioner Marty Makary, M.D., M.P.H., in the agency’s press release. The decision came 61 days after biologics license application filing. Tied for fastest modern FDA BLA approval.
Priority Voucher Paves Accelerated Path
This wasn’t standard review. Regeneron used the Commissioner’s National Priority Voucher pilot, launched to speed rare disease therapies. Sixth approval overall; first gene therapy. The program coordinates multi-center reviews, slashing timelines from 10-12 months to weeks. Continued approval hinges on durability data, speech development, and quality-of-life measures. FDA plans a June 4 public meeting for feedback, with comments due June 29.
Regeneron committed big. Otarmeni free for eligible U.S. patients. George Yancopoulos, president and chief scientific officer, called it “a huge scientific leap” in the company’s announcement. Affects 20-50 U.S. newborns yearly. OTOF variants cause 2-8% of nonsyndromic congenital deafness cases.
Patient impacts stun. In CHORD, one child heard whispers months post-dose. Another conversed normally with family. Biospace reported David Whitton, a trial investigator, noting a treated ear responding three weeks in: “That’s beautiful.” (Biospace, April 25, 2026). NPR highlighted the milestone for rare deafness forms. (NPR, April 23, 2026).
Challenges remain. Dual-vector delivery demands precision; off-target risks low but monitored. Long-term expression unproven fully. Accelerated status means confirmatory trials ahead. Still, 11 of 12 in CHORD core cohort improved meaningfully. Zero serious adverse events tied to the therapy.
Broader implications loom. Gene therapies now target neurosensory deficits. Regeneron eyes expansions. Competitors eye GJB2, TMC1 mutations—far commoner. Reuters noted the approval’s rarity: first for otoferlin-related loss. (Reuters, April 23, 2026). Pharmaphorum detailed CHORD: nine of 12 ditched implants post-treatment. (Pharmaphorum, April 27, 2026).
Industry watches. ASGCT hailed it a “major milestone.” (ASGCT, April 24, 2026). Free access sets precedent amid pricing debates. Regeneron stock ticked up post-news, per market reports.
Rare today. Template tomorrow. Otarmeni proves gene delivery can rebuild hearing pathways. For those kids hearing mom’s voice anew? Priceless.
WebProNews is an iEntry Publication